Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 105-115 , February 2010

111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors

  • Conrad Chan

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3M2
    • ,
  • Zhongli Cai

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3M2
    • ,
  • Ruifen Su

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3M2
    • ,
  • Raymond M. Reilly

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3M2
    • Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada M5S 3E2
    • Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada M5G 2M9
    • Corresponding Author InformationCorresponding author. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada M5S 3M2. Tel.: +1 416 946 5522; fax: +1 416 978 8511.

Received 10 August 2009 ,Revised 6 September 2009 ,Accepted 2 October 2009.

References 

  1. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039
  2. Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta. 2006;1765:155–177
  3. Mitra A, Nan A, Papadimitriou JC, Ghandehari H, Line BR. Polymer–peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol. 2006;33:43–52
  4. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–1159
  5. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186–198
  6. Dijkgraaf I, Kruijtzer JAW, Frielink C, Corstens FHM, Oyen WGJ, Liskamp RMJ, et al. αvβ3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer. 2006;120:605–610
  7. Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H, Amano R, et al. αvβ3 integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer. 2008;123:709–715
  8. Reilly RM. Biomolecules as targeting vehicles for in situ radiotherapy of malignancies. In:  Knaeblein J,  Mueller R editor. Modern biopharmaceuticals: design, development and optimization. Weinheim, Germany: Wiley-VCH; 2005;p. 497–526
  9. Chan C, Sandhu J, Guha A, Scollard DA, Wang J, Chen P, et al. A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for 111In for imaging tumor angiogenesis. J Nucl Med. 2005;46:1745–1752
  10. Reilly RM. The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. In:  Gad SC editors. Handbook of biopharmaceutical technology. Toronto, Canada: John Wiley & Sons; 2007;p. 987–1053
  11. Chen P, Wang J, Hope K, Lin L, Dick J, Cameron R, et al. Nuclear localizing sequences (NLS) promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47:827–836
  12. Waibel R, Alberto R, Willuda J, Finnern R, Schibi R, Stichelberger A, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897–901
  13. Ito N, Huang K, Claesson-Welsh L. Signal transduction by VEGF receptor-1 wild type and mutant proteins. Cell Signal. 2001;13:849–854
  14. Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R. Cell uptake and radiotoxicity studies of a nuclear localization signal peptide-intercalator conjugate labeled with [99mTc(CO3]+. Bioconjug Chem. 2005;16:582–587
  15. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med. 2008;49:1353–1361
  16. Lechner A, Blaickner M, Gianolini S, Poljanc K, Aiginger H, Georg D. Targeted radionuclide therapy: theoretical study of the relationship between tumour control probability and tumour radius for a P-32/P-33 radionuclide cocktail. Phys Med Biol. 2008;53:1961–1974
  17. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys. 1992;19:1371–1383
  18. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 1996;271:5638–5646
  19. Costantini D, Chan C, Cai Z, Vallis KA, Reilly RM. 111In-trastuzumab (Herceptin) modified with nuclear localizing sequences (NLS): a novel Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357–1368
  20. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 2008;23:3–24
  21. Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vesicular function. Circ Res. 2006;98:743–756
  22. Lejbkowicz F, Goldberg-Cohen I, Levy AP. New horizons for VEGF. Is there a role for nuclear localization?. Acta Histochem. 2005;106:405–411
  23. Agorastos N, Borsig L, Renard A, Antoni P, Viola G, Spingler B, et al. Cell-specific and nuclear targeting with [M(CO)3]+ (M=99mTc, Re)-based complexes conjugated to acridine orange and bombesin. Chem Eur J. 2007;13:3842–3852

PII: S0969-8051(09)00239-X

doi: 10.1016/j.nucmedbio.2009.10.001

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 105-115 , February 2010

Article Tools

* Image Usage & Resolution